RANTES (regulated on activation normal T cell expressed) has been found at elevated levels in biological fluids from patients with a wide range of allergic and autoimmune diseases and is able to attract several subtypes of leukocytes including eosinophils and monocytes into inflamed tissue. Amino-terminal modifications of RANTES produce receptor antagonists which are candidates for blocking this cellular recruitment. Met-RANTES has been shown to modulate inflammation in vivo, while AOP-RANTES is a potent inhibitor of R5 human immunodeficiency virus type 1 (HIV-1) strains and has been shown to down-modulate CCR5 and prevent recycling of the receptor. We have studied the effect of AOP-RANTES in eosinophil activation and have found that it is able to efficiently elicit eosinophil effector functions through CCR3, as measured by the release of reactive oxygen species and calcium mobilization, whereas Met-RANTES is inactive in these assays. AOP-RANTES is found to inhibit CCR3-mediated HIV-1 infection with moderate potency, in contrast to its potent inhibition of CCR5-mediated HIV-1 infection. Furthermore, we have investigated the abilities of these modified proteins to down-modulate CCR1 and CCR3 from the surface of monocytes and eosinophils. We show here that AOP-RANTES is much less effective than RANTES in down-modulation of CCR1. Surprisingly, recycling of CCR1 was minimal after incubation with RANTES while there was complete recycling with AOP-RANTES. In the case of CCR3, no significant difference was found between RANTES and AOP-RANTES in down-modulation and recycling. It therefore appears that trafficking of RANTES receptors follows different patterns, which opens up potential new targets for therapeutic intervention.
Chemokines are chemotactic proteins that play a central role in immune and inflammatory responses by the attraction and activation of leukocytes. They can be divided into two major classes on the basis of the arrangement of the amino acid cysteine in the amino-terminal region: the CXC and CC chemokines, and two minor subclasses, each comprising a single member, the C and CX3C subclasses (1) (2) (3) . Initially, it was generally accepted that the chemokine subclasses differ in their biological activity to stimulate different kinds of leukocytes, so that CXC chemokines are mediators of acute inflammation through neutrophil activation while the CC chemokines mediate chronic inflammation by attracting leukocytes such as eosinophils, monocytes, lymphocytes, basophils, and dendritic cells. However, this paradigm has recently been shown to have exceptions; for example, CXCR3 is expressed on activated T cells (4) and neutrophils can be activated by CC chemokines following stimulation with interferon-␥ (5).
Chemokines mediate their effects by binding to cell-surface receptors that belong to the seven-transmembrane domain G protein-coupled receptor superfamily (1) . More recently, chemokine receptors have been subject to intense scrutiny following the discovery that several of them are co-receptors for HIV 1 cell entry (6) . In this context, the CC chemokine receptor CCR5 and the CXC chemokine receptor, CXCR4, function as the major co-receptors for HIV infection in vivo, while several other receptors, including CCR3, have been demonstrated to act as coreceptors in vitro (7) The expression of chemokine receptors is under the control of pro-inflammatory cytokines such as interleukin-2 (8) and interferon-␥ (5), and is thus modified during disease. Chemokine receptors are therefore an attractive target for therapeutic intervention both for inflammation and infection by viruses such as HIV. To this end, several kinds of chemokine receptor antagonists have been developed (9) . It is well known that the NH 2 -terminal region is critical for the biological activity of chemokines, and therefore modifications of this region of a chemokine can profoundly alter the activity of the chemokines on leukocytes. Thus modified chemokines such as Met-RAN-TES (10), AOP-RANTES (11), RANTES (3-68) (12) , MCP-1(9 -68) (13) , and others were constructed by deletion or extension of amino acids or by chemical modification of the NH 2 -terminal residue of CC chemokines. In vivo studies using these analogues have proved the concept that chemokine receptor blockade is effective in preventing inflammation in several animal models; for example, Met-RANTES administration reduced the inflammation in a model of crescentic glomerulonephritis (14) , collagen-induced arthritis (15) , airways inflammation (16) , and heterologous renal transplants (17) . In addition, MCP-1(9 -68) administration was highly effective in preventing the symptoms associated with arthritis in mice that spontaneously develop this condition (18). Furthermore, a virally produced chemokine, vMIP-II encoded by herpesvirus-8 has also been shown to be effective in preventing nephritis (19) .
AOP-RANTES, a potent inhibitor of CCR5-mediated HIV-1 infection, has been shown to be capable of activating CCR5 in transfected cell lines, as well as in primary cells (20, 21, 46) . In order to investigate the therapeutic potential of RANTES modifications in allergic or autoimmune disease we have further analyzed the activity of RANTES, AOP-RANTES and Met-RANTES in their ability to activate CCR3 in eosinophils, and to down-modulate CCR1 and CCR3 from monocytes and eosinophils respectively. We present results that demonstrate that while AOP-RANTES is capable of acting on CCR3 to activate eosinophils, its effects on CCR1 and CCR3 endocytosis are significantly different to those seen on CCR5. Surprisingly, we describe that RANTES induces prolonged down-regulation of CCR1, while AOP-RANTES does not. Finally, in contrast to the potent anti-infectivity properties on R5 HIV-1 viruses, the addition of the pentacarbon chain to the NH 2 terminus of RAN-TES to form AOP-RANTES does not confer particularly potent inhibitory properties for R3 HIV-1 viral infection.
MATERIALS AND METHODS

Chemokines and Chemokine Receptor Antagonists-Met-RANTES
and AOP-RANTES were prepared as described previously (10, 11) . Eotaxin and eotaxin-2 were obtained from PeproTech Inc. (London, United Kingdom). C5a was obtained from Sigma Chemicals (Deisenhofen, Germany).
Monoclonal Antibodies-The mouse mAb against human CCR1 (IgG2b) was obtained from R&D Systems (Minneapolis, MN). Anti-CCR3 (IgG2a, clone 7B11) was prepared as described previously (23) or was obtained from R&D Systems. The mouse mAb against human CCR5 (IgG1, clone MC-1) was prepared as described previously (20) . The murine IgG1, IgG2a and IgG2b isotype control antibodies were obtained from Immunotech (Hamburg, Germany). The rat IgG2a isotype control antibody was from PharMingen (San Diego, CA).
Cell Isolation-Human granulocytes were isolated from heparinanticoagulated venous blood from non-atopic healthy donors using Ficoll (Amersham Pharmacia Biotech) density gradient centrifugation as described previously (24) . For further purification, granulocytes were resuspended in HEPES-buffered Hanks' balanced salt solution (HBSS; Life Technologies, Inc.), pH 7.4, containing 1 mg/ml BSA (HBSSϩBSA). Eosinophils were purified by negative selection with Dynabeads M-450 (Dynal, Hamburg, Germany) coated with anti-CD16 antibody (clone 3G8, Dianova, Hamburg, Germany) as described previously (24) . The resulting eosinophil purity was 99.5%, as determined by microscopic examination with Kimura staining and flow cytometric analysis (FACScan ® , Becton Dickinson, Heidelberg, Germany) using phycoerythrinconjugated anti-CD16 antibody (clone 3G8, Dianova, Hamburg, Germany) (24) . Receptor down-modulation on monocytes was carried out using total blood without prior isolation of the monocytes. For this purpose, freshly drawn EDTA-blood was diluted 10-fold with phosphate-buffered saline, centrifuged for 8 min at 300 ϫ g, resuspended in RPMI, recentrifuged, and then resuspended in RPMI at a cell density of approximately 10 ϫ 10 6 /ml and used directly. The monocytes were distinguished from the other leukocyte populations on the basis of their forward and side light scatter properties by flow cytometry.
Calcium Mobilization-Eosinophils were loaded with 2 M fura-2-AM (Molecular Probes), and [Ca 2ϩ ] i was measured at 37°C in an Aminco Bowman Series 2 spectrofluorometer (SLM-Aminco, Urbana, IL) as described previously (25) . Autofluorescence represents approximately 10% of the total fluorescence of cells loaded with fura-2, and it is slightly greater at 340 nm than at 380 nm. The fluorescence of unloaded cells was therefore subtracted from an equivalent density of cells loaded with fura-2 to correct the signal for autofluorescence. The autofluorescence of the cells was virtually unchanged upon addition of stimulus. Dual excitation spectra were collected at 340 and 380 nm, and emission was fixed at 510 nm.
Lucigenin-dependent Chemiluminescence-Lucigenin-dependent chemiluminescence was measured using a single-photon imaging system with a two-dimensional photon counting system which allows the simultaneous measurement and analysis of 96 wells (MTP Reader, Hamamatsu Photonics, Herrsching, Germany) as described elsewhere (26) . In brief, eosinophils were suspended at a density of 5 ϫ 10 4 cells/ml in HBSSϩBSA containing 200 M lucigenin (Sigma). Aliquots (100 l) containing 5 ϫ 10 3 eosinophils were placed into flat-bottomed white microtiter plates (Microfluor, Dynatech, Denkendorf, Germany). Cells were stimulated by the indicated stimuli or medium as a control. Measurements were performed in triplicate at 37°C. Integral counts from 0 to 60 min incubation intervals after addition of the stimuli to the cell sample were measured and expressed as intensity integral counts. Data are expressed as the original plots or ratio between stimulusinduced intensity integral counts and medium-induced intensity integral counts.
Toxin Treatment-Pertussis toxin (Calbiochem Novabiochem, San Diego, CA) treatment was performed by incubation of 1 ϫ 10 6 cells/ml for 120 min at 37°C with and without 2 g/ml pertussis toxin as described elsewhere (26) . The cells were then washed and resuspended in test medium prior to the measurement of reactive oxygen species release induced by the ligands. Viability of eosinophils after toxin treatment was more than 95%, as assessed by propidium iodide (Molecular Probes, Eugene, OR) staining in flow cytometry.
Virus Infection Assays-U87/CD4/CCR3 cells are a human osteosarcoma cell line stably expressing human CD4 and CCR3 and were a kind gift from Dan Littman (Skirball Institute, New York, NY). Duplicates of U87/CD4/CCR3 cells set up overnight at 1 ϫ 10 4 cells/well in 48-well trays (Costar) were exposed to 75 l of chemokine at twice the required final concentration for 30 min at 37°C. 2000 focus-forming units of the R3R5X4 HIV-1 strain, 2028 (27) , in 75 l was added to each well. After 3 h of incubation, the cells were washed three times and fresh medium containing chemokine at the required concentration was added. After another 3 days of incubation, the cells were fixed in cold methanol: acetone (1:1) and immunostained for HIV-1 p24 gag antigen as described previously (28) . Infected foci stained blue and were counted by light microscopy, and focus-forming units/ml were calculated.
Down-modulation and Recycling of Chemokine Receptors-Cells were incubated in a total volume of 100 l of RPMI for 30 min at 37°C in an incubator or on ice with various concentrations of chemokines. RPMI alone was used as the control. For recycling experiments, cells were washed three times with 3 ml of RPMI at room temperature and further incubated at 37°C. Aliquots were taken at the times indicated and stained for receptor surface expression as described below.
Staining and Flow Cytometry-All staining procedures were performed on ice, and centrifugation steps were carried out at 2°C. Cells were centrifuged and resuspended in RPMI containing 10 g/ml antichemokine receptor mAb or isotype control. After 60 min, the cells were washed three times in ice-cold phosphate-buffered saline and incubated with a fluorescein isothiocyanate/phycoerythrin-labeled rabbit antimouse F(ab)2 fragment (F313/R439, Dako, Hamburg, Germany). After two washing steps, the cells were analyzed on a FACS-Calibur (BectonDickinson, Mountain View, CA). Lymphocytes, monocytes, and granulocytes were distinguished by their forward and side scatter properties. Statistical Analysis-Unless otherwise stated, the data in the text and figures were expressed as mean Ϯ standard error of the mean (S.E.). Analysis of variance was used for comparing experimental groups to the control value. When the global test of differences was significant at the 5% level, pairwise tests of differences between groups were applied (Student's t test for paired data using 5% significance level, closed test procedure).
RESULTS
RANTES Receptor Expression on Normal Human Eosinophils-
The eosinophils from healthy non-atopic donors used in these experiments were screened for their profile of the RAN-TES receptors CCR1, CCR3, and CCR5 by flow cytometry using the appropriate monoclonal antibodies. CCR3 was the receptor most highly expressed on eosinophils, although a significant expression of CCR1 was detectable (Fig. 1) . Surface expression of CCR5 was undetectable.
AOP-RANTES-induced Eosinophil Effector
Functions-The release of reactive oxygen species can be induced by several chemokines, eotaxin and eotaxin-2 being the most potent ( Fig.  2A and Ref. 26 ). Met-RANTES was unable to induce the release of reactive oxygen species at the concentrations tested from 0.125 ϫ 10 Ϫ10 to 1.25 ϫ 10 Ϫ7 M in human eosinophils (Fig. 2B) . In contrast to Met-RANTES, AOP-RANTES showed an identical activity to RANTES in this assay, which is less potent that eotaxin and eotaxin-2 (Fig. 2B) . Similarly, no calcium mobilization was observed for Met-RANTES at 1.25 ϫ 10 Ϫ8 M (data not shown), whereas RANTES and AOP-RANTES gave a robust response at this concentration (Fig. 3) . In heterologous desensitization experiments, RANTES almost completely desensitized the response induced by an equivalent concentration (1.25 ϫ 10 Ϫ8 M) of eotaxin ( Fig. 3B ), but AOP-RANTES was unable to do so, since eotaxin, when applied 90 s later, still gave a larger calcium flux (Fig. 3D) . When the order of addition was reversed, homologous desensitization was observed in both cases (Fig. 3, A and C) . We were able to determine if the receptor responsible for calcium mobilization was CCR3 by using the blocking monoclonal anti-CCR3 antibody, 7B11 (Fig.  4) . Treatment with this antibody abolished the responses induced by both RANTES (data not shown) and AOP-RANTES, as well as that induced by eotaxin, while no effect was observed on the response induced by C5a.
The dependence of the release of reactive oxygen species in response to the CCR3 ligands on G protein coupling was investigated by pre-incubation of the eosinophils with pertussis toxin. Pre-treatment with pertussis toxin completely abolished the response to eotaxin, eotaxin-2, RANTES, and AOP-RAN-TES (Fig. 5) . The viability of the eosinophils after incubation with the toxin was found to be greater than 95%, as assessed by flow cytometry following propidium iodide staining.
Inhibition of R3R5X4 HIV-1 Strain 2028 in U87/CD4/CCR3 Cells-The infection of human osteosarcoma cells that express CD4 and CCR3 by the HIV-1 strain 2028, which can use either CCR3, CCR5, or CXCR4 for entry, has been used to assess the inhibitory properties of CCR3 ligands. The most potent inhibitor was the virally encoded vMIP-II, as has been previously reported (29) , which had an IC 50 value of 3 nM in this assay. Eotaxin, the most efficacious CCR3 ligand, was also very potent, with an IC 50 value of 4.2 nM, but it did not achieve the complete inhibition shown by VMIP-II. RANTES was less efficient, and only reached half-maximal inhibition at 100 nM. Mip-1␣, in accordance with its lack of CCR3 activity, was inactive in inhibiting viral infection. AOP-RANTES was moderately effective, with an IC 50 value of 15 nM (Fig. 6) .
Ligand-induced Receptor Down-regulation-CCR3 downregulation from the surface of eosinophils was monitored by pre-incubating the cells with 1.25 ϫ 10 Ϫ7 M AOP-RANTES, Met-RANTES, eotaxin, and medium for 30 min at 4°C and at 37°C. The cells were then stained with the anti-CCR3 mAb and receptor expression measured by flow cytometry. The loss of surface CCR3 induced by ligand binding at 37°C was presumed to be due to its down-modulation rather than altered receptor accessibility to the antibody, since ligand binding was not affected when measured at 4°C, a temperature at which receptor internalization is prevented.
The down-modulation of CCR3 on eosinophils showed some donor to donor variability. In one donor, eotaxin was significantly more potent than RANTES and AOP-RANTES (Fig. 7A) , whereas, in two other donors, RANTES induced the same degree of down-modulation as eotaxin. In all donors, however, AOP-RANTES was equipotent to RANTES in inducing downmodulation. Met-RANTES was unable to induce any significant down-modulation of CCR3.
The ability of the RANTES proteins to down-regulate CCR1 was investigated on freshly isolated monocytes rather than on eosinophils due to the significantly higher CCR1 expression level in the former cell type. Met-RANTES was unable to induce CCR1 endocytosis at concentrations as high as 3.75 M (Fig. 8A ), as has been described in CHO transfectants expressing CCR1 (30) . AOP-RANTES showed only weak activity in inducing CCR1 down-regulation, attaining only 30 -40% at micromolar concentrations, whereas RANTES was able to achieve 80% removal of the cell surface CCR1.
Recycling of CCR1 and CCR3-We were interested in the effect that the modified RANTES protein, AOP-RANTES, would have on the recycling of the other RANTES receptors, CCR1 and CCR3, in view of the fact that it prevented CCR5 from recycling to the cell surface in peripheral blood mononuclear cells (20) . After 30 min of incubation with the various ligands (1.25 ϫ 10 Ϫ7 M) for CCR3 on eosinophils and CCR1 on monocytes, the cells were washed three times to remove unbound ligand, and then re-incubated at 37°C for the times indicated in Figs. 7B and 8B. After 2 h, 60 -80% of the CCR3 receptor density was again detectable on the cell surface, following down-modulation by all the ligands tested, eotaxin, RANTES, and AOP-RANTES. After 24 h, the receptor level of CCR3 on eosinophils had reached 70 -90% of their original number (data not shown). Thus, the AOP-RANTES-treated eosinophils behaved in a similar manner to the other ligand treated cells with respect to CCR3 recycling.
AOP-RANTES only moderately down-regulates CCR1 achieving a maximum of 40% removal of cell surface CCR1. Over a period of 3 h following removal of AOP-RANTES, the CCR1 receptors were again detectable on the surface of the monocytes, attaining their original receptor density. Surprisingly, after removal of RANTES from the medium, no recycling of CCR1 was observed over the 3-h period. DISCUSSION The observation that modification of the amino-terminal region of chemokines affects receptor activation and produces receptor antagonists has been made by several laboratories. Two such modified RANTES proteins, which have extensions at the amino terminus, have been reported to be potent antagonists. Met-RANTES, produced by the retention of the initiating methionine during expression in E. coli, is a potent inhibitor of RANTES-and MIP-1␣-induced effects in THP-1 cells as well as T cells (10) . Furthermore, it has been shown to be efficacious in preventing inflammation in several animal models of disease (15-17, 31, 32) . The second, AOP-RANTES, produced by the chemical coupling of a penta-carbon alkyl chain to the oxidized amino-terminal serine residue, had no agonist activity in monocyte chemotaxis and is a very potent inhibitor of HIV-1 infection (11). However, we have observed that AOP-RANTES is a full agonist of CCR5 in receptor endocytosis and receptor phosphorylation, which are not G protein-coupled events, whereas Met-RANTES is only weakly active (20, 21) . We have recently further investigated the abilities of these two proteins to activate CCR1, CCR3, and CCR5 in transfected cells via G protein-coupled signaling as measured by calcium mobilization, as well as their ability to induce chemotaxis (46) . We were therefore interested in the ability of AOP-RANTES to activate the other RANTES receptors, CCR1 and CCR3, in primary cells. Eosinophils from normal donors express high levels of CCR3 (50,000 -400,000/cell) (23, 33, 34) as well as low levels of CCR1, which range from 1% to 5% that of CCR3 (33) . While eosinophils from certain patients express the message for other chemokine receptors, the evidence for high levels of other functional receptors remains circumstantial (46) . We have confirmed by flow cytometry that the eosinophils used in this study express high levels of CCR3, as well as significant levels of CCR1 but no detectable CCR5.
FIG. 3. Eotaxin-induced heterologous desensitization to AOP-RANTES in eosinophils.
We have been able to show that AOP-RANTES is equipotent to RANTES in inducing eosinophil activation as demonstrated by the release of reactive oxygen species, but both are less potent than the CCR3-specific ligands, eotaxin and eotaxin-2. AOP-RANTES is, however, less active than RANTES in mobilizing calcium stores since it is not able to desensitize the mobilization induced by eotaxin. This lowered activity in comparison to RANTES correlates with its lowered efficacy in mediating chemotaxis through CCR3 in the murine pre-B lymphoma cell line L1.2, transfected with this receptor (46) . Eosinophil activation by AOP-RANTES appears to be mediated through CCR3 since a neutralizing anti-CCR3 antibody abrogates the AOP-RANTES-mediated effects. The activation of eosinophils by AOP-RANTES through CCR3 and not CCR1 is in agreement with its poor activity on CCR1 (21, 46) . Finally, AOP-RANTES activates CCR3 through the classic G proteincoupled pathway since treatment with pertussis toxin also abrogates the reactive oxygen species release induced by AOP-RANTES as well as by the other CCR3 ligands tested. On the other hand, Met-RANTES is not able to activate CCR3 and has been shown to inhibit eosinophil functions principally through CCR1 (35) .
AOP-RANTES is the most potent inhibitor of R5 HIV-1 strains described to date (11) . However, this property appears to be specific for CCR5, since AOP-RANTES was only moderately effective at inhibiting CCR3-mediated infection of the R3R5X4 HIV-1 strain 2028 (27) that is able to use several receptors for entry, in cells only expressing CCR3. The inhibitory properties of AOP-RANTES correlate well with its affinity for CCR3, which is greater than RANTES itself, but less than the high affinity ligand eotaxin (46) . The addition of the pentacarbon alkyl chain with the aminooxy linker appears to confer a special property to the AOP-RANTES protein in its interaction with CCR5 resulting in potent HIV-1 inhibition, perhaps due to its ability to prevent cell surface CCR5 expression, but this interaction does not appear to effect CCR3. Thus AOP-RANTES is not a pan-inhibitor of all HIV-1 strains, since its potent effects are restricted to R5 strains.
The ability of chemokines to induce receptor sequestration is not dependent on G protein coupling (36) . However, it is well documented that endocytosis of seven transmembrane receptors is an agonist triggered event requiring phosphorylation of the carboxyl-terminal region (21, 37, 38) . We have previously shown that the CC chemokine receptor antagonist, Met-RAN-TES, is unable to trigger the events leading to CCR1 internalization in CHO/CCR1 transfectants (30) , and here we show its inability to induce down-regulation of CCR1 on primary cells such as monocytes. While AOP-RANTES can induce endocytosis of CCR1, its activity is greatly reduced compared with RANTES. This lowered activity is correlated by its weak ability to phosphorylate CCR1 (21) . However, AOP-RANTES is shown here to be comparable to RANTES in its ability to induce down-regulation of CCR3.
It should be noted, however, that it was recently reported that RANTES was significantly more potent than eotaxin at inducing CCR3 endocytosis (39) . We have observed that eotaxin and RANTES are equivalent in this activity on eosinophils from two donors, but that cells from a third donor showed an enhanced sensitivity to eotaxin as compared with RANTES in the down-modulation of CCR3. Donor to donor variation in reactivity of eosinophils toward RANTES and eotaxin has previously been reported (23) . Eotaxin is certainly more potent than RANTES in inducing other activities in eosinophils such as ROS release, which correlates with its higher affinity for this receptor (23, 33) . While receptor internalization is not mediated by G protein coupling, the other chemokinemediated effects are, and both should depend on binding affinity for the receptor. Thus, while we do not have an explanation for this discrepancy, factors such as donor to donor variation, the source of the recombinant chemokines, the stability of the chemokines in vitro as well as the experimental conditions used in different laboratories could contribute to different relative potencies. It should be noted, for example, that the eosinophils used in the report by Zimmerman et al. (39) were always conducted in the presence of interleukin-5, whereas the experiments described in this report did not include interleukin-5 in the culture medium. Finally, CCR3 binding has been shown to be extremely sensitive to experimental conditions such as ionic strength and pH (40) , which could affect relative ligand potencies observed in different laboratories.
Finally, this study has highlighted significant differences on the recycling patterns of the three RANTES receptors: CCR1, CCR3, and CCR5. AOP-RANTES has previously been described to prevent the recycling of CCR5, whereas RANTES treatment allows it to recycle to the surface (20) . This effect has been suggested to contribute to the very potent anti-HIV infectivity properties of this derivative. In addition, CCR5 does not appear to be degraded after down-regulation, since the receptors regain their original density in the presence of cycloheximide. CXCR2 has been described to undergo a different fate, since it is targeted to the lysosomal compartment and degraded (41) . Zimmerman et al. have reported that CCR3 appears to follow both pathways, since it is partially degraded, but a proportion is able to recycle (39) . The fate of CCR1 is currently being addressed in our laboratory. However, it appears to behave in a manner totally opposite to CCR5; recycling after AOP-RANTES treatment is not prevented at all, while recycling after treatment with RANTES is prevented. It may be argued that this is not an effect of the modification on the AOP-RANTES protein, but rather that, since AOP-RANTES is not very potent at inducing down-regulation, the receptor is not driven into a compartment that maintains it inside the cell. However, we feel that the observation of the prolonged internalization of CCR1 after RANTES treatment and removal of the ligand from the medium may be highly significant. RAN-TES was recently also shown to retard CCR3 recycling com- FIG. 5 . Reactive oxygen species (ROS) release is mediated by a G i protein-coupled pathway. The release of reactive oxygen species release was measured using lucigenin-dependent chemiluminescence. Eosinophils were preincubated with medium and 2 g/ml pertussis toxin, respectively, prior to the addition of ligand as described under "Materials and Methods." Viability of eosinophils after toxin treatment was more than 95% as assessed by propidium iodide staining in flow cytometry. Human eosinophils were then stimulated with AOP-RAN-TES, Met-RANTES, eotaxin, and eotaxin-2. Pertussis-treated eosinophils are shown in shaded bars, and the ligand-stimulated controls in open bars. Data (n ϭ 6) are expressed as the ratio of relative reactive oxygen species release by ligand-stimulated and medium-treated cells. Global differences between groups: p Ͻ 0.001 (analysis of variance); **, p Ͻ 0.001 compared with medium-pretreated cells (Student's t test). pared with eotaxin over an 18-h period (39) , but these experiments were carried out in the continued presence of ligand, whereas in our experiments the ligand was removed.
The chemokine system has been defined as an extremely redundant system, with multiple ligand binding patterns for several receptors and certain ligands that are able to activate several receptors. However, it must be remembered that this binding characterization has been performed in vitro, and that there must be many levels of control in vivo. These control mechanisms are starting to be elucidated. Receptor and chemokine expression, at least for the inducible chemokines, is thought to play a role in inflammation. Pro-inflammatory cytokines are thought to be responsible for the up-regulation of chemokine receptors, and several studies have demonstrated these effects (8, (42) (43) (44) . Another possible mechanism contributing to in vivo specificity is selective binding demonstrated by heterologous binding studies with a virally encoded chemokine receptor, US28 (45) , as well as different cellular backgrounds (22) . We believe that differential trafficking pathways of chemokine receptors after activation may be an important mechanism, which confers yet another level of specificity to this system, commonly described as being highly redundant from in vitro ligand binding and activation studies. The question now remains to be addressed as to whether low receptor levels in disease samples may in fact be due to the fact that this receptor is in reality extremely important in a particular situation and that after it has performed its role, it is removed from the cell surface. Ϫ7 M RANTES (E) and AOP-RANTES (q), the cells were washed three times with medium. The cells were then incubated at 37°C, and surface CCR1 was analyzed at the time points indicated. The data shown represent one experiment from three separate experiments.
